Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-9137255b",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514",
  "action": "critique",
  "content": "I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.\n\n## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor\n\n**Specific Weaknesses:**\n- The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43\n- No direct evidence that DNAJB6 inhibits cross-seeding between different protein types\n- The cited PMIDs don't actually support cross-seeding inhibition claims\n\n**Counter-evidence:**\n- DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID: 28302677)\n- HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins (PMID: 30833379)\n- DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful (PMID: 23064266)\n\n**Alternative Explanations:**\n- DNAJB6 effects on polyglutamine may not generalize to other aggregation-prone proteins\n- Disease associations could reflect developmental or other non-aggregation-related functions\n\n**Key Falsifying Experiments:**\n- Test DNAJB6 overexpression in tau-α-synuclein co-aggregation assays\n- Examine whether DNAJB6 enhancer compounds reduce cross-seeding in mixed pathology animal models\n- Assess whether DNAJB6 activity correlates with cross-seeding inhibition across protein pairs\n\n**Revised Confidence:** 0.35\n\n## Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance\n\n**Specific Weaknesses:**\n- No evidence that engineered TREM2 can distinguish cross-seeded from homologous aggregates\n- TREM2 engineering for specific protein recognition remains largely theoretical\n- The cited evidence doesn't support selective clearance claims\n\n**Counter-evidence:**\n- TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation (PMID: 32719357)\n- TREM2 activation may promote rather than clear certain protein aggregates in some contexts (PMID: 33568819)\n- Engineered immune receptors often lose specificity and cause off-target effects (PMID: 31171062)\n\n**Alternative Explanations:**\n- TREM2 disease associations may reflect inflammatory rather than clearance mechanisms\n- Cross-seeded aggregates may not have unique recognition signatures\n\n**Key Falsifying Experiments:**\n- Test whether engineered TREM2 constructs can selectively bind cross-seeded vs. homologous aggregates\n- Examine clearance efficiency in mixed vs. single pathology models\n- Assess whether TREM2 enhancement reduces or increases aggregate burden\n\n**Revised Confidence:** 0.25\n\n## Hypothesis 3: Prohibitin-2 Mitochondrial Cross-Seeding Hub\n\n**Specific Weaknesses:**\n- Limited evidence for prohibitin-2 as a direct cross-seeding platform\n- Mitochondrial targeting specificity remains unproven\n- The cited PMIDs don't demonstrate cross-seeding hub function\n\n**Counter-evidence:**\n- Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging (PMID: 28007915)\n- TDP-43 mitochondrial localization may be secondary to other pathological processes (PMID: 29899071)\n- Prohibitin complex disruption often reflects rather than causes neurodegeneration (PMID: 31591533)\n\n**Alternative Explanations:**\n- Protein-prohibitin interactions may be consequences rather than causes of pathology\n- Mitochondrial dysfunction could be downstream of aggregation rather than facilitating it\n\n**Key Falsifying Experiments:**\n- Demonstrate direct cross-seeding between proteins at prohibitin-2 complexes\n- Test whether prohibitin-2 modulation affects cross-seeding independent of mitochondrial dysfunction\n- Examine temporal relationships between prohibitin disruption and cross-seeding\n\n**Revised Confidence:** 0.30\n\n## Hypothesis 4: RNA-Binding Competition Therapy\n\n**Specific Weaknesses:**\n- Limited evidence for RNA-mediated cross-seeding as a major mechanism\n- Aptamer delivery to brain and cellular uptake challenges not addressed\n- No proof that blocking TDP-43-RNA interactions prevents cross-seeding\n\n**Counter-evidence:**\n- TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic (PMID: 31570834)\n- RNA aptamers show poor CNS penetration and rapid degradation (PMID: 32284562)\n- TDP-43 pathology often involves loss rather than gain of RNA binding function (PMID: 32296184)\n\n**Alternative Explanations:**\n- TDP-43-tau mRNA interactions may be protective rather than pathogenic\n- Cross-seeding may occur through direct protein interactions rather than RNA scaffolding\n\n**Key Falsifying Experiments:**\n- Test whether RNA aptamers actually reduce cross-seeding in cellular models\n- Examine whether blocking TDP-43 RNA binding affects normal vs. pathological protein interactions\n- Assess aptamer brain penetration and target engagement\n\n**Revised Confidence:** 0.20\n\n## Hypothesis 5: Transglutaminase-2 Cross-Linking Inhibition\n\n**Specific Weaknesses:**\n- TG2 cross-linking may stabilize rather than initiate aggregation\n- Selectivity for cross-seeding-specific sites is unproven\n- Limited evidence that TG2 is required for cross-seeding\n\n**Counter-evidence:**\n- TG2 activity can be protective in some neurodegeneration contexts (PMID: 27784544)\n- TG2 cross-linking often occurs after aggregate formation, not during initial seeding (PMID: 25242045)\n- Non-selective TG2 inhibition causes significant toxicity (PMID: 28847752)\n\n**Alternative Explanations:**\n- TG2 cross-linking may be a secondary stabilization mechanism\n- Elevated TG2 could reflect compensatory rather than pathogenic responses\n\n**Key Falsifying Experiments:**\n- Test whether TG2 inhibition prevents initial cross-seeding vs. just aggregate stability\n- Examine temporal relationships between TG2 activation and cross-seeding initiation\n- Assess selectivity of proposed inhibitors for pathological vs. physiological substrates\n\n**Revised Confidence:** 0.40\n\n## Hypothesis 6: Liquid-Liquid Phase Separation Modifier Therapy\n\n**Specific Weaknesses:**\n- Phase separation modulators lack specificity for pathological vs. physiological condensates\n- Limited evidence that stress granule mixing drives cross-seeding\n- Surface tension modulation could disrupt essential cellular processes\n\n**Counter-evidence:**\n- Stress granules may be protective by sequestering aggregation-prone proteins (PMID: 31959759)\n- Phase separation is essential for normal cellular function, making modulation risky (PMID: 33658718)\n- Many phase separation modulators are toxic at effective concentrations (PMID: 32296183)\n\n**Alternative Explanations:**\n- Protein co-localization in condensates may not lead to pathological cross-seeding\n- Phase separation changes could be adaptive responses to stress\n\n**Key Falsifying Experiments:**\n- Test whether preventing stress granule formation reduces or increases protein aggregation\n- Examine selectivity of modulators for pathological vs. physiological condensates\n- Assess whether cross-seeding requires condensate mixing or just proximity\n\n**Revised Confidence:** 0.35\n\n## Hypothesis 7: Glycosaminoglycan Template Disruption\n\n**Specific Weaknesses:**\n- GAGs are essential for normal cellular functions, limiting therapeutic window\n- Targeted delivery to achieve selectivity remains challenging\n- Evidence for GAG-mediated cross-seeding is primarily correlative\n\n**Counter-evidence:**\n- GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways (PMID: 31969712)\n- Heparan sulfate may actually protect against some forms of protein aggregation (PMID: 26755048)\n- GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues (PMID: 29728651)\n\n**Alternative Explanations:**\n- GAG-protein interactions may be protective sequestration mechanisms\n- GAG changes in disease may reflect rather than cause pathology\n\n**Key Falsifying Experiments:**\n- Test whether GAG removal prevents cross-seeding without affecting normal protein folding\n- Examine whether selective GAG modification reduces cross-seeding in vivo\n- Assess delivery methods for achieving therapeutic selectivity\n\n**Revised Confidence:** 0.45\n\n## Summary Assessment:\n\nThe hypotheses suffer from common weaknesses:\n1. Limited direct evidence for cross-seeding mechanisms\n2. Lack of specificity for pathological vs. physiological processes  \n3. Delivery and selectivity challenges not adequately addressed\n4. Reliance on correlative rather than mechanistic evidence\n5. Potential for significant off-target effects\n\nMost confidence scores should be substantially reduced due to these fundamental limitations in evidence and feasibility.",
  "tokens_used": "2150",
  "persona_id": "persona-skeptic"
}